{"id":"W3167506953","doi":"10.1200/jco.2021.39.15_suppl.6011","title":"Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Carboplatin; Clinical endpoint; Internal medicine; Oncology; Nivolumab; Head and neck cancer; Response Evaluation Criteria in Solid Tumors; Cetuximab; Radiation therapy; Cancer; Surgery; Clinical trial; Progressive disease; Chemotherapy; Cisplatin; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001023766,0.001011296,0.001280916,0.0003372851,0.0002216103,0.001317832,0.0007534315,0.0008642153,0.003547884],"category_scores_gemma":[0.0005691357,0.000520152,0.001557917,0.0002498745,0.0004934458,0.0007631639,0.0004473698,0.002509694,0.0007308139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00117478,"about_ca_system_score_gemma":0.0008729434,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009178485,"about_ca_topic_score_gemma":0.003077727,"domain_scores_codex":[0.9997393,0.0001021318,0.00001253042,0.00005714058,0.00002503272,0.00006381213],"domain_scores_gemma":[0.9997832,0.00003251583,0.0000546829,0.00002233297,0.00001233964,0.00009479893],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8205951,0.01535178,0.00576619,0.001883132,0.002260834,0.0001355312,0.0001953637,0.005788101,0.01328171,0.0008356613,0.008859624,0.1250469],"study_design_scores_gemma":[0.8139923,0.157604,0.0127679,0.0003378608,0.001459294,0.0003529349,0.00008666851,0.004562278,0.002234123,0.0009238772,0.005621658,0.00005707858],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775638,0.010551,0.0005302677,0.0009166932,0.0003544056,0.002121601,0.002024411,0.0001655171,0.005772281],"genre_scores_gemma":[0.9817433,0.003475855,0.001776075,0.001672394,0.0002619233,0.002452995,0.002946877,0.00004160893,0.005628974],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003547884,"threshold_uncertainty_score":0.01186883,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1190708390398879,"score_gpt":0.4638345405171012,"score_spread":0.3447637014772132,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}